Altimmune Inc.

3.57+0.4100+12.97%Vol 100.33M1Y Perf -70.71%
Dec 1st, 2023 16:00 DELAYED
BID3.61 ASK3.62
Open5.74 Previous Close3.16
Pre-Market- After-Market3.74
 - -  0.17 4.76%
Target Price
29.71 
Analyst Rating
Strong Buy 1.33
Potential %
732.21 
Finscreener Ranking
★★★★     53.40
Insiders Trans % 3/6/12 mo.
-43/-50/-50 
Value Ranking
★★★★     56.13
Insiders Value % 3/6/12 mo.
-98/-98/-98 
Growth Ranking
★★★+     54.07
Insiders Shares Cnt. % 3/6/12 mo.
-96/-97/-97 
Income Ranking
 —    -
Price Range Ratio 52W %
9.81 
Earnings Rating
Strong Buy
Market Cap191.81M 
Earnings Date
7th Nov 2023
Alpha0.06 Standard Deviation0.47
Beta-0.11 

Today's Price Range

3.525.87

52W Range

2.0917.17

5 Year PE Ratio Range

-4.201.20

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
27.05%
1 Month
39.45%
3 Months
34.72%
6 Months
-16.20%
1 Year
-70.71%
3 Years
-69.87%
5 Years
-0.56%
10 Years
-94.73%

TickerPriceChg.Chg.%
ALT3.570.410012.97
AAPL191.241.29000.68
GOOG133.32-0.6000-0.45
MSFT374.51-4.4000-1.16
XOM102.990.25000.24
WFC45.020.43000.96
JNJ158.383.72002.41
FB196.640.99000.51
GE122.500.70000.57
JPM156.840.76000.49
Financial StrengthValueIndustryS&P 500US Markets
13.10
13.40
0.00
0.01
-671.10
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-2 621.30
-2 616.80
-534.50
-
RevenueValueIndustryS&P 500US Markets
42.00K
0.00
-20.44
-9.55
Earnings HistoryEstimateReportedSurprise %
Q03 2023-0.40-0.392.50
Q02 2023-0.44-0.3227.27
Q01 2023-0.49-0.4018.37
Q04 2022-0.52-0.4317.31
Q03 2022-0.49-0.482.04
Q02 2022-0.45-0.426.67
Q01 2022-0.57-0.4422.81
Q04 2021-0.64-0.4923.44
Earnings Per EndEstimateRevision %Trend
12/2023 QR-0.3424.44Positive
12/2023 FY-1.4310.63Positive
3/2024 QR-0.4625.81Positive
12/2024 FY-1.4512.65Positive
Next Report Date-
Estimated EPS Next Report-0.40
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume100.33M
Shares Outstanding53.73K
Shares Float51.53M
Trades Count496.79K
Dollar Volume455.88M
Avg. Volume1.33M
Avg. Weekly Volume1.61M
Avg. Monthly Volume1.20M
Avg. Quarterly Volume1.18M

Altimmune Inc. (NASDAQ: ALT) stock closed at 3.57 per share at the end of the most recent trading day (a 12.97% change compared to the prior day closing price) with a volume of 100.33M shares and market capitalization of 191.81M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 43 people. Altimmune Inc. CEO is Vipin K. Garg.

The one-year performance of Altimmune Inc. stock is -70.71%, while year-to-date (YTD) performance is -78.3%. ALT stock has a five-year performance of -0.56%. Its 52-week range is between 2.09 and 17.17, which gives ALT stock a 52-week price range ratio of 9.81%

Altimmune Inc. currently has a PE ratio of -7.50, a price-to-book (PB) ratio of 3.43, a price-to-sale (PS) ratio of 16 351.20, a price to cashflow ratio of 0.10, a PEG ratio of -, a ROA of -37.62%, a ROC of -42.35% and a ROE of -41.97%. The company’s profit margin is -%, its EBITDA margin is -2 616.80%, and its revenue ttm is $42.00 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Altimmune Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.40 for the next earnings report. Altimmune Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Altimmune Inc. is Strong Buy (1.33), with a target price of $29.71, which is +732.21% compared to the current price. The earnings rating for Altimmune Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Altimmune Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Altimmune Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 23.41, ATR14 : 0.39, CCI20 : 351.72, Chaikin Money Flow : -0.74, MACD : 0.19, Money Flow Index : 97.80, ROC : 46.31, RSI : 77.48, STOCH (14,3) : 35.30, STOCH RSI : 1.00, UO : 34.86, Williams %R : -64.70), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Altimmune Inc. in the last 12-months were: David J. Drutz (Buy at a value of $39 294), Eisenstadt Richard (Buy at a value of $43 100), Eisenstadt Richard (Sold 0 shares of value $0 ), Garg Vipin (Sold 0 shares of value $0 ), GILL JOHN (Sold 2 714 shares of value $40 710 ), M. .Scot Roberts (Sold 0 shares of value $0 ), M. Scot Roberts (Option Excercise at a value of $0), M. Scott Harris (Buy at a value of $42 200), M. Scott Harris (Sold 0 shares of value $0 ), Matthew Scott Harris (Buy at a value of $42 200), Matthew Scott Harris (Option Excercise at a value of $0), Richard I. Eisenstadt (Option Excercise at a value of $0), Vipin K. Garg (Option Excercise at a value of $0), Wayne Pisano (Option Excercise at a value of $52 000), Wayne Pisano (Sold 20 000 shares of value $300 268 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (83.33 %)
5 (83.33 %)
6 (85.71 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (16.67 %)
1 (16.67 %)
1 (14.29 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.33
Strong Buy
1.33
Strong Buy
1.29

Altimmune Inc.

Altimmune Inc is a United States-based clinical-stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of liver diseases. The firm's product candidates include NasoVAX, HepTcell, SparVax-L, and NasoShield. It also develops platform technologies such as RespirVec and Densigen. The company generates its revenue from cost plus fee contracts and fixed-price contracts.

CEO: Vipin K. Garg

Telephone: +1 240 654-1450

Address: 910 Clopper Road, Gaithersburg 20878, MD, US

Number of employees: 43

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

64%36%

 

TipRanks News for ALT

Wed, 08 Nov 2023 17:00 GMT Analysts Offer Insights on Healthcare Companies: Altimmune (ALT) and SurModics (SRDX)

- TipRanks. All rights reserved.

Tue, 07 Nov 2023 19:40 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Altimmune (ALT), Zimmer Biomet Holdings (ZBH) and Esperion (ESPR)

- TipRanks. All rights reserved.

Wed, 11 Oct 2023 04:15 GMT Altimmunes Obesity Treatment Pemvidutide: A Potential Market Leader with Favorable Risk/Reward Ratio

- TipRanks. All rights reserved.

Tue, 12 Sep 2023 15:05 GMT Altimmune (ALT) Receives a Buy from JMP Securities

- TipRanks. All rights reserved.

Fri, 01 Sep 2023 16:35 GMT Altimmune (ALT) Gets a Buy from B.Riley Financial

- TipRanks. All rights reserved.

Mon, 14 Aug 2023 16:01 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Altimmune (ALT) and Zynerba Pharmaceuticals (ZYNE)

- TipRanks. All rights reserved.

Thu, 10 Aug 2023 22:15 GMT Altimmune (ALT) Gets a Buy from JMP Securities

- TipRanks. All rights reserved.

News

Stocktwits